HeliMeds names its dispensing pharmacy, says plainly that it is not one itself, and prints a potency tolerance as an actual number. It also sells its flagship weight-loss product on a page that never once names the drug, so no price could be filed against it.
What HeliMeds charges
Tirzepatide: $149 — restated as $149 a month but billed $447 once, for twelve weeks
Tirzepatide: $232 — restated as $232 a month but billed $697 once, for twelve weeks; $697 divided by three is $232.33, which the page rounds
Sermorelin: $239/mo — per month for one vial; a three-vial first order works out at $129 a month
NAD+: $99/mo — per month, and the page footnotes it: "price with the first order of 12-month package"
HeliMeds is not a paid partner; this link may earn a commission if that changes. Full disclosure.
By Nora Castellan, Standards EditorUpdated September 2026
A URL is not a product name
Its semaglutide page prices a product at two monthly rungs, but the word semaglutide appears nowhere in that page's visible text.
The product is headed "Personalized Compounded GLP-1", and the only molecules named in the copy are two brand names inside a disclaimer.
The drug name lives in the web address and nowhere a reader can see it, so nothing is filed for semaglutide here.
Its own terms give two different answers about states
One clause reads "We are currently servicing every state except California and Alaska".
Ten sections later in the same document: "The Services are currently available to individuals located in certain states. To see the list of current states, please click contact customer service."
Both are recorded and neither is corrected. One document cannot both name the exclusions and refuse to publish the list, and the seller does not say which sentence is current.
The testing claims are specific, and undocumented
It states a potency tolerance as a number — the medication is confirmed within ten per cent either side of the intended concentration — and says the test runs every three to six months.
It cites a named USP chapter for sterility and shows green "Passed" badges beside the claims.
No certificate of analysis is published. That makes this a specific and checkable-sounding testing claim rather than testing evidence, and it is recorded as a claim.
What each price actually buys
Its tirzepatide rungs are restated as monthly rates but billed once for a twelve-week supply, at a starter dose and at every dose above it.
Its sermorelin figure prints a vial size and a volume beside the price, and it notes that a three-vial first order works out cheaper per month.
Its NAD+ headline rate is footnoted as the price with a first order of the twelve-month package, which is a different commitment from the monthly figure it sits beside. Its terms also carry another brand's pharmacy network in an unedited clause, immediately after naming its own.
Who it's for
Readers buying sermorelin who want the vial size printed beside the price.
Buyers who will read the footnote under a headline rate before ordering.
Shoppers who want the dispensing pharmacy named and the seller's own role stated.
Anyone who wants a potency tolerance given as a number rather than a promise.
Who should look elsewhere
Buyers shopping semaglutide on price, since its page never names the drug.
Readers who need a straight answer about whether their state is served.
Anyone who wants a certificate of analysis rather than a passed badge.
Shoppers who want a monthly commitment rather than a twelve-week one.
Strengths
Names its dispensing pharmacy and says plainly that it is not one itself
States its potency tolerance as a number and names the sterility chapter
Prints the vial size and volume beside its sermorelin figure
Says its compounded medicine is not FDA-approved, in those words
Trade-offs
Its weight-loss product page never names the drug it sells, so no price could be filed for it
Its own terms give two incompatible answers about which states it serves
Its NAD+ headline price is footnoted as the twelve-month first-order rate
Its terms carry another brand's pharmacy network in an unedited clause
How we verified this
Read the weight-loss product page's visible text in full, confirmed the drug is named nowhere on it, and filed no price against semaglutide.
Read both state clauses in the same terms document and recorded them as they stand, without choosing between them.
Read each price with its own qualifier, confirming which figures bill once for twelve weeks and which headline rate is footnoted to a twelve-month first order.
Requested a deliberately meaningless address on this host in the same session and confirmed it returns a not-found response.
Screened the brand, its legal entity and its named pharmacy against the live federal warning-letter table through a matcher that normalises both the query and the filed company name before comparing, and found no letters.
A provider to compare HeliMeds against
Trellis Vitality
Trellis Vitality frames its program around body-composition tracking rather than scale weight, pairing NAD+, glutathione and tesamorelin with at-home biomarker panels and a 90-day re-test, and names its dispensing pharmacy, VialsRX in Houston, by address.
No price is recorded for it. The page that sells the product never names the drug in its visible text, and a web address is not a product name.
Which states does it serve?
Its own terms answer twice and disagree. One clause says every state except California and Alaska; another says availability is limited to certain states and tells readers to contact customer service for the list.
Is the medicine tested?
It claims a test every three to six months confirming the active ingredient is within ten per cent either side of the intended concentration, and cites a USP chapter for sterility. No certificate is published, so this is a claim.
Am I paying monthly for tirzepatide?
No. Both tirzepatide rungs are restated as monthly rates but billed once, up front, for a twelve-week supply.
HeliMeds is not a paid partner; this link may earn a commission if that changes. Full disclosure.